Day One Biopharmaceuticals Inc’s recently made public that its HEAD OF R&D Blackman Samuel C. unloaded Company’s shares for reported $0.16 million on Apr 18 ’24. In the deal valued at $16.02 per share,10,000 shares were sold. As a result of this transaction, Blackman Samuel C. now holds 1,174,662 shares worth roughly $17.53 million.
Then, Blackman Samuel C. sold 10,000 shares, generating $160,055 in total proceeds. Upon selling the shares at $16.01, the HEAD OF R&D now owns 1,184,662 shares.
Before that, Blackman Samuel C. sold 30,000 shares. Day One Biopharmaceuticals Inc shares valued at $457,314 were divested by the HEAD OF R&D at a price of $15.24 per share. As a result of the transaction, Blackman Samuel C. now holds 1,194,662 shares, worth roughly $17.82 million.
Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy in a research note published on April 24, 2024; the price target was $33. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in late April from “a Buy” to “an Underperform”. CapitalOne began covering DAWN with “an Overweight” recommendation on February 08, 2023. Oppenheimer started covering the stock on February 03, 2023. It rated DAWN as “a Perform”.
Price Performance Review of DAWN
On Friday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 12.94% to $14.92. Over the last five days, the stock has lost -0.27%. Day One Biopharmaceuticals Inc shares have risen nearly 2.19% since the year began. Nevertheless, the stocks have risen 17.48% over the past one year. While a 52-week high of $17.85 was reached on 03/01/24, a 52-week low of $9.67 was recorded on 04/25/24. SMA at 50 days reached $15.20, while 200 days put it at $13.56. A total of 3.6 million shares were traded, compared to the trading of 4.62 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 13.73, which if violated will result in even more drops to 12.55. On the upside, there is a resistance level at 15.60. A further resistance level may holdings at 16.29. The Relative Strength Index (RSI) on the 14-day chart is 50.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.27, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.52%. Stochastics %K at 30.08% indicates the stock is a holding.
The most recent change occurred on December 15, 2022 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
